NAV Loans in Private Equity: What LPs Don't Know Can Hurt Them
According to ILPA guidance on NAV facilities , the following analysis reflects current market conditions and publicly available data. NAV Loans in Private Equity: What LPs Don't Know Can Hurt Them bod
NAV Loans in Private Equity: What LPs Don't Know Can Hurt Them
In 2023, the Institutional Limited Partners Association (ILPA) issued formal guidance recommending that limited partners receive explicit consent rights before their GPs enter into NAV financing facilities. ILPA published that guidance because the market had grown so fast, and disclosed so little, that limited partners across institutional and family-office allocations were finding out about fund-level borrowing after the fact. Sometimes years after the fact. That's not a hypothetical problem. I've spoken with LPs who discovered their fund had a NAV facility only during the GP's next fundraise, buried in a data room document they almost didn't open.
What a NAV Loan Actually Is
A NAV loan (short for net asset value loan) is a credit facility extended to a private equity fund. The collateral is the fund's portfolio of investments. The lender, usually a bank or alternative credit manager, advances money based on a percentage of the fund's estimated net asset value. That percentage is called the loan-to-value ratio, or LTV. Typical LTVs run between 10% and 25% of portfolio value. On a $1 billion fund, that means the GP could draw $100 million to $250 million.
The mechanics work like this. The GP identifies a lender and negotiates facility terms. Pricing has stabilized in a range of 4% to 7% above the benchmark rate, according to Rede Partners' 2026 NAV Financing Market Report. The portfolio companies serve as collateral, often through a pledge of the fund's ownership interests in those companies. The facility sits at the fund level, above portfolio company debt but below LP capital commitments in the capital structure. When lenders want to protect themselves, they include cross-collateralization clauses. That's the clause that should keep you up at night.
Cross-collateralization means every portfolio company backs the whole loan. If one company's valuation drops sharply, it can trigger a covenant breach across the entire facility, even if every other company in the portfolio is performing fine. The lender can then demand accelerated repayment, charge penalty rates, or in extreme cases, move to foreclose on the pledged interests.
Why GPs Love Them
From a GP's perspective, NAV loans solve real operational problems. Private equity funds are illiquid by design. Capital is locked up in companies that may not be ready for exit for three to five more years. But the fund still has expenses. Portfolio companies may need follow-on capital. And LPs, who are themselves under pressure to show distributions, want cash back.
A NAV loan gives the GP dry powder without forcing a sale. If the best company in the portfolio is performing well but the exit market is unfavorable, the GP doesn't have to sell at a discount to fund the next deal. They can borrow against the portfolio instead. In a world where IPO windows close and M&A activity slows, that flexibility has genuine value.
Subscription credit lines (borrowing against LP commitments) have been standard in PE for years. NAV loans are the logical extension of that same principle to later in the fund lifecycle, after LP commitments are mostly drawn. Ropes and Gray's 2026 analysis of fund finance markets confirms that NAV facilities have become mainstream across private equity, private credit, and real assets. The market isn't exotic anymore. It's a standard tool.
Why You, as an LP, Should Be Concerned
The flexibility is real. The risks are also real. Here are the four that matter most.
Hidden Debt Load
When you committed capital to a private equity fund, you received a pitch book. That pitch book described a return profile. That return profile assumed a certain amount of debt — typically at the portfolio company level. It did not account for fund-level borrowing sitting on top. NAV loans add a second layer of debt to your investment. If the portfolio declines, losses are amplified. You took on more risk than the original pitch described.
DPI Manipulation
This is the 2026 issue that regulators are watching most closely. DPI stands for distributions to paid-in capital. It's how much cash you've received back relative to what you invested. A high DPI signals that a fund actually returned money, not just paper gains. When GPs are raising a new fund, DPI is one of the first numbers institutional investors check.
Some GPs are now using NAV loan proceeds specifically to fund LP distributions before launching a new fundraise. The LP receives a cash distribution. The DPI number improves. The GP then goes to market with a better-looking track record. The underlying portfolio hasn't changed. No company was sold. The cash came from a loan that the fund now owes back, with interest. You got your cash, but your fund is now indebted to pay for it. That's an optics play funded by debt, and it's a direct conflict of interest between GP fundraising incentives and LP economic interests.
Cross-Collateral Risk
I described this above, but it's worth repeating because the math can be shocking. Imagine a fund with ten portfolio companies. One company hits a rough patch and its valuation drops 40%. The NAV loan covenant specifies that the overall portfolio LTV cannot exceed 20%. That single company's decline pushes the aggregate LTV over the threshold. The lender demands a cure. The GP must either inject fresh capital, sell an asset quickly, or pay down the facility. That forced sale may happen at a bad time, at a bad price, affecting a company the GP would never have sold otherwise.
Disclosure Gaps
Most LP agreements written before 2018 do not explicitly authorize or prohibit NAV-level borrowing. GPs have used broad language around general partner authority to justify entering NAV facilities without LP consent or even formal notice. You may not know the facility exists. You may not know the size. You almost certainly don't receive quarterly reporting on LTV ratios and covenant headroom.
NAV Loan Uses Ranked by LP Risk Level
| Use of Proceeds | GP Rationale | LP Risk Level | Key Concern |
|---|---|---|---|
| Follow-on investments in existing portfolio companies | Protects pro-rata without forcing exits | Low to Medium | Only problematic if companies are already struggling |
| Bridge financing for near-term exits | Monetizes value before formal closing | Low | Short duration. Proceeds tied to an identified exit |
| New platform investments | Extends fund deployment without raising new capital | Medium | Extends fund life. Adds risk to end-of-life portfolio |
| Fund operating expenses | Covers management costs when portfolio is illiquid | Medium | Signals cash flow stress. Adds permanent cost to LPs |
| LP distributions (recurring) | Returns capital to LPs under liquidity pressure | High | Debt-funded distributions obscure actual realization rates |
| LP distributions to boost DPI pre-fundraise | Improves track record optics for GP's next fund | Very High | Direct conflict of interest. Regulatory scrutiny increasing |
What Your LP Agreement Probably Says (or Doesn't)
Pull your limited partnership agreement and look for language around fund-level borrowing. Most LPAs from before 2018 contain a clause granting the GP broad authority to borrow money on behalf of the fund. That clause was written with subscription lines in mind. It almost certainly does not specify NAV facilities. It almost certainly does not set a cap on fund-level debt as a percentage of NAV. It almost certainly does not require LP consent or notice before the GP draws on a NAV facility.
ILPA's 2023 guidance is direct on this point. They recommend that new fund agreements include explicit authorization language for NAV facilities, separate from general borrowing authority. They recommend that facilities above a specified size threshold (say, 10% of NAV) require LP advisory committee consent. They recommend quarterly reporting on facility utilization and covenant status. Most funds formed before 2022 have none of this language. Some funds formed after 2022 still don't.
If you are currently in due diligence on a new fund commitment, ask for the fund's form LPA. Find the borrowing authority section. Ask specifically whether the GP intends to use NAV financing. Ask what consent mechanisms apply. If the answer is "our standard GP authority covers it," that answer is not acceptable. Push for an explicit side letter provision if the LPA language is inadequate.
What the SEC Is Watching
The SEC's Division of Examinations has identified NAV loan disclosures as a priority area. A senior SEC examiner stated publicly that the agency is scrutinizing both NAV loans and subscription lines, looking specifically at whether fund managers are disclosing these facilities accurately in their ADV filings, fund documents, and LP communications. The examination program focuses on three things.
First, valuation integrity. Lenders who extend NAV facilities retain the right to challenge portfolio company valuations independently. The SEC wants to see that GPs are not inflating valuations to maintain borrowing capacity. Second, conflict-of-interest documentation. When the lender has a relationship to the GP (for example, when a GP-affiliated entity is the lender) the SEC expects thorough disclosure and process documentation showing the facility is on arm's-length terms. Third, the use of proceeds. Specifically, regulators want to understand whether distributions funded by NAV loans are disclosed to LPs as debt-funded rather than realization-funded.
The SEC has not yet brought a major enforcement action specifically on NAV loan disclosure as of mid-2026. That does not mean one isn't coming. The examination focus typically precedes enforcement by 12 to 24 months. If you are an LP and your GP has a NAV facility, it is worth verifying that the fund's most recent ADV Part 2 discloses the facility's existence and purpose.
5 Questions to Ask Your GP Before Approving Any Fund-Level Borrowing
- Does our LPA explicitly authorize NAV-level borrowing? Ask to see the specific clause. If the GP cites general borrowing authority, ask whether that language was intended to cover facilities collateralized by portfolio assets. If the answer is unclear, request a legal opinion from independent fund counsel.
- What is the total facility size, the current LTV, and how is portfolio valuation determined for borrowing base purposes? You need the numbers, not the narrative. Get the facility term sheet. Understand who determines portfolio company valuations for NAV purposes. Ask whether the lender uses an independent valuation agent and how often marks are updated.
- Are any distributions being funded from NAV loan proceeds rather than asset realizations? This is the DPI manipulation question. Some GPs will dodge it. A straight answer is "yes, the distribution in Q4 2025 was funded partially by a draw on our NAV facility." Any answer that doesn't directly address the source of the cash is incomplete.
- What triggers could force accelerated repayment or increased interest rates, and how far is the portfolio from those triggers today? Get the covenant package in writing. Understand the LTV floor, the coverage ratios, and any portfolio concentration limits. Ask the GP to model what happens to covenant headroom if the top two portfolio companies decline 30% in value.
- What ongoing reporting will LPs receive on facility usage and covenant compliance? Quarterly is the minimum acceptable frequency. You should receive the facility's outstanding balance, the current LTV, a summary of any covenant waivers or amendments, and a description of how proceeds were used. If the GP resists providing this, that resistance tells you something important about how they view LP oversight.
Not All NAV Loans Are Bad
I want to be clear about something. A NAV facility used to fund a value-accretive follow-on investment, where the GP believes a portfolio company needs capital to capture a market opportunity and the exit horizon is well-defined, is a legitimate tool. It keeps the GP from forcing a secondary sale at a discount just to raise cash. It can improve LP outcomes in a genuine way.
A bridge facility drawn for six to nine months against a portfolio company that has signed a sale agreement, used to advance distributions ahead of a formal closing, is also generally fine. The underlying value has been established. The loan is short-dated. The risk is bounded.
The problem isn't the instrument. The problem is opacity, conflicts of interest, and using fund-level debt to manufacture performance optics. If your GP is transparent about the facility, discloses its purpose, limits its use to investment-oriented activities, and gives you reporting, you can make an informed judgment. That's all LPs are asking for. That's what ILPA's guidance is asking for. It is not an unreasonable ask.
The $100 billion NAV loan market is here to stay. Bank-led facilities have tripled in median deal size over the past several years. Alternative lenders are entering the space. Smaller funds are using these tools, not just the megafunds. The question isn't whether NAV financing exists in your portfolio. The question is whether you know about it, whether you've reviewed the terms, and whether the use of proceeds aligns with your interests as an LP. If you haven't asked those questions yet, now is the time.
This article is for informational purposes only and does not constitute investment advice, legal advice, or a solicitation to buy or sell any security or fund interest. Private equity investments are speculative, illiquid, and involve a high degree of risk including the possible loss of principal. Consult qualified legal and financial advisors before making any investment decision.
Looking for investors?
Browse our directory of 750+ angel investor groups, VCs, and accelerators across the United States.
About the Author
Jeff Barnes, MBA
Continue Reading
Bain Capital Acquires Vitabiotics for $850M: What PE Buyers See in Consumer Health
Bain Capital India Insurance: PE's Emerging Markets Financial Services Play
Vesterra Capital Acquires PHFM: Inside the Facilities Management Roll-Up Thesis
Tech PE in 2026: What Francisco Partners' $21.2B Record Close Signals for LP Allocators
How to Buy LP Stakes on the Private Equity Secondary Market
